We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-12.75%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$4.02B
AUM Growth
+$78.1M
Cap. Flow
+$805M
Cap. Flow %
20.04%
Top 10 Hldgs %
52.6%
Holding
62
New
8
Increased
9
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
MXCT icon
MaxCyte
MXCT
+$211M
2
ABSI icon
Absci
ABSI
+$150M
3
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$140M
4
PACB icon
Pacific Biosciences
PACB
+$88.6M
5
DNA icon
Ginkgo Bioworks
DNA
+$87.7M

Top Sells

Rank Stock Value
1
AMRS
Amyris Inc.
AMRS
+$49.1M
2
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$45.3M
3
NEO icon
NeoGenomics
NEO
+$22.1M
4
FULC icon
Fulcrum Therapeutics
FULC
+$12.1M
5
CLOV icon
Clover Health Investments
CLOV
+$9.68M

Sector Composition

Rank Sector Weight
1 Healthcare 91.14%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVTA
1
DELISTED
Invitae Corporation
NVTA
$347M 8.64%
12,203,669
– –
BLFS icon
2
BioLife Solutions
BLFS
$1.56B
$320M 7.97%
7,566,292
+126,185
+2% +$6.08M
EXAS
3
DELISTED
Exact Sciences
EXAS
$225M 5.61%
2,360,186
– –
PACB icon
4
Pacific Biosciences
PACB
$444M
$204M 5.08%
7,990,652
+2,990,652
+60% +$88.6M
FATE icon
5
Fate Therapeutics
FATE
$294M
$202M 5.02%
3,400,000
– –
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$29.1B
$189M 4.7%
1,000,000
– –
MXCT icon
7
MaxCyte
MXCT
$116M
$171M 4.25%
+13,971,334
New +$211M
BPMC
8
DELISTED
Blueprint Medicines
BPMC
$159M 3.97%
1,550,000
– –
SLGC
9
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$154M 3.82%
+12,389,082
New +$140M
VERV
10
DELISTED
Verve Therapeutics
VERV
$143M 3.55%
3,038,167
– –
RLAY icon
11
Relay Therapeutics
RLAY
$4.04B
$116M 2.88%
3,668,574
+293,516
+9% +$9.88M
TWST icon
12
Twist Bioscience
TWST
$5.97B
$107M 2.66%
1,000,000
– –
SRPT icon
13
Sarepta Therapeutics
SRPT
$1.63B
$102M 2.53%
1,100,000
+215,000
+24% +$16.6M
CDXS icon
14
Codexis
CDXS
$157M
$101M 2.51%
4,330,000
– –
AGIO icon
15
Agios Pharmaceuticals
AGIO
$1.84B
$99.9M 2.49%
2,165,000
– –
ABSI icon
16
Absci
ABSI
$1.34B
$89.8M 2.23%
+7,718,593
New +$150M
DNLI icon
17
Denali Therapeutics
DNLI
$3.67B
$85.8M 2.13%
1,700,000
+90,000
+6% +$5.07M
DNA icon
18
Ginkgo Bioworks
DNA
$580M
$83.5M 2.08%
+180,070
New +$87.7M
IPSC icon
19
Century Therapeutics
IPSC
$353M
$80.7M 2.01%
3,206,380
– –
RVMD icon
20
Revolution Medicines
RVMD
$38.8B
$77M 1.92%
2,800,000
+495,000
+21% +$14.4M
CDNA icon
21
CareDx
CDNA
$2.48B
$75.6M 1.88%
1,193,335
– –
TNYA icon
22
Tenaya Therapeutics
TNYA
$161M
$74.1M 1.84%
+3,586,818
New +$77.1M
BEAM icon
23
Beam Therapeutics
BEAM
$2.66B
$71.2M 1.77%
818,820
– –
TNGX icon
24
Tango Therapeutics
TNGX
$4.43B
$71M 1.77%
+5,487,910
New +$65.8M
DMTK
25
DELISTED
DermTech, Inc. Common Stock
DMTK
$56M 1.39%
1,745,000
– –
1
2 3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Casdin Capital held 62 positions worth $4.02B, up 2% from $3.94B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Casdin Capital deployed $805M of net new capital in Q3 2021, opening 8 new positions and adding to 9 existing holdings. Its largest new stake was MaxCyte: 13,971,334 shares worth $171M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was 23andMe Holding Co, an estimated $8M trimmed.

  • Casdin Capital's largest Q3 2021 buy was MaxCyte: 13,971,334 shares worth $171M.
  • Casdin Capital added most to Pacific Biosciences in Q3 2021, an estimated $88.6M increase.
  • Casdin Capital's biggest Q3 2021 reduction was 23andMe Holding Co, cutting an estimated $8M.
  • Casdin Capital fully exited Amyris Inc. in Q3 2021, selling an estimated $49.1M.
  • Casdin Capital's ten largest holdings make up 53% of its $4.02B portfolio in Q3 2021.
  • Casdin Capital opened 8 new positions and closed 8 in Q3 2021.
  • Casdin Capital's portfolio value rose 2% quarter-over-quarter to $4.02B.

Based on Casdin Capital's 13F filing for Q3 2021, filed 15 Nov 2021.